These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37235924)

  • 1. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!
    Katsiki N; Rizzo M; Mikhailidis DP
    J Diabetes Complications; 2023 Jul; 37(7):108510. PubMed ID: 37235924
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
    Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E
    Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism.
    Liang B; Li R; Zhang P; Gu N
    J Cardiovasc Transl Res; 2023 Apr; 16(2):327-340. PubMed ID: 35969357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study.
    Patoulias D; Papadopoulos C; Zografou I; Katsimardou A; Karagiannis A; Doumas M
    Medicina (Kaunas); 2022 Aug; 58(9):. PubMed ID: 36143844
    [No Abstract]   [Full Text] [Related]  

  • 6. Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.
    Liang B; Gu N
    Int J Med Sci; 2022; 19(7):1118-1121. PubMed ID: 35919809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes.
    Hussain M; Elahi A; Hussain A; Iqbal J; Akhtar L; Majid A
    J Diabetes Res; 2021; 2021():9973862. PubMed ID: 34239940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin.
    La Grotta R; de Candia P; Olivieri F; Matacchione G; Giuliani A; Rippo MR; Tagliabue E; Mancino M; Rispoli F; Ferroni S; Berra CC; Ceriello A; Prattichizzo F
    Cell Mol Life Sci; 2022 May; 79(5):273. PubMed ID: 35503137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
    Sharma A; Wu J; Ezekowitz JA; Felker GM; Udell JA; Heidenreich PA; Fonarow GC; Mahaffey KW; Hernandez AF; DeVore AD
    ESC Heart Fail; 2020 Feb; 7(1):274-278. PubMed ID: 31747132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ANMCO Position paper: Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in diabetic patients and for the treatment of heart failure patients with and without diabetes].
    Gronda E; Napoli C; Iacoviello M; Urbinati S; Caldarola P; Mannucci E; Colivicchi F; Gabrielli D
    G Ital Cardiol (Rome); 2021 Aug; 22(8):675-687. PubMed ID: 34310573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of sodium glucose co-transporter inhibitors in heart failure prevention.
    Garla V; Subauste A; Butler J; Lien LF
    J Diabetes Complications; 2021 Mar; 35(3):107811. PubMed ID: 33280983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.
    Kokhan E; Kiyakbaev G; Medovchshikov V
    Eur J Heart Fail; 2022 Jul; 24(7):1323-1324. PubMed ID: 35238461
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease.
    Solomon J; Festa MC; Chatzizisis YS; Samanta R; Suri RS; Mavrakanas TA
    Pharmacol Ther; 2023 Feb; 242():108330. PubMed ID: 36513134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
    Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis.
    Giugliano D; Longo M; Caruso P; Maiorino MI; Bellastella G; Esposito K
    Diabetes Obes Metab; 2021 Jul; 23(7):1672-1676. PubMed ID: 33710721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.
    Suijk DLS; van Baar MJB; van Bommel EJM; Iqbal Z; Krebber MM; Vallon V; Touw D; Hoorn EJ; Nieuwdorp M; Kramer MMH; Joles JA; Bjornstad P; van Raalte DH
    Clin J Am Soc Nephrol; 2022 May; 17(5):663-671. PubMed ID: 35322793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure.
    Attachaipanich T; Chattipakorn SC; Chattipakorn N
    J Cell Physiol; 2022 May; 237(5):2404-2419. PubMed ID: 35324001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review.
    Supakul S; Nishikawa Y; Teramura M; Takase T
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.
    Kumar S; Khatik GL; Mittal A
    Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.